Navigation Links
Molecular basis for neurodegeneration in Ataxia telangiectasia

An upcoming paper from Dr. David Wassarman (University of Wisconsin School of Medicine and Public Health) in the May 1 issue of G&D lends new insight into the pathogenesis of neurodegeneration in Ataxia telangiectasia.

Ataxia telangiectasia (A-T) is a rare, genetic immunodeficiency disease that affects multiple organ systems and is characterized by neurodegeneration and cancer predisposition. A-T is caused by recessive mutations in the ataxia telangiectasia mutated (ATM) gene.

While existing animal models have established how ATM mutations contribute to genomic instability and cancer susceptibility, Dr. Wassarmans paper reveals how ATM mutations cause neurodegeneration.

The scientists generated a Drosophila model of A-T, in which neurodeneneration occurs in the absence of induced DNA damage as it does in human A-T patients. Thus, Dr. Wassarmans model most faithfully recapitulates neurodegeneration associated with the human disease.

Using this model, Dr. Wassarman and colleagues determined ATM functions normally to prevent neurons from re-entering the cell cycle.

At the end of the day, ATM-dependent arrest of cell growth is critical for both neuron function and tumor suppression, explains Dr. Wassarman. Furthermore, he is excited by the findings, as they point to possible therapeutic potential of CDC25 and other cell cycle inhibitors to treat A-T as well as other neurodegenerative disorders.


Contact: Heather Cosel-Pieper
Cold Spring Harbor Laboratory

Page: 1

Related biology news :

1. ESF conference probes waters mysterious interactions at molecular level
2. Power of molecular imaging reveals secrets of the heart
3. Computer simulations point to key molecular basis of cystic fibrosis
4. New edition of a classic molecular biology textbook from CSHL Press and Benjamin Cummings
5. Molecular Biology of the Cell celebrates 25 years of publication
6. Shilatifard Lab sheds light on molecular machinery required for translation of histone crosstalk
7. How molecular muscles help cells divide
8. Leading cause of death in preemies might be controlled by resetting a molecular switch
9. Pennsylvania Hospital surgeon receives grant to develop molecular cardiac surgery
10. NIH selects LIAI for major study on allergy molecular causes and possible treatments
11. Potential new therapeutic molecular target to fight cancer
Post Your Comments:
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
(Date:3/22/2016)... , PROVO and ... Newborn Screening Ontario (NSO), which operates the highest sample ... molecular testing, and Tute Genomics and UNIConnect, leaders in ... respectively, today announced the launch of a project to ... (NGS) testing panel. NSO has been ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... Seattle, WA (PRWEB) , ... June 23, 2016 ... ... technology, announces the release of its second eBook, “Clinical Trials Patient Recruitment and ... patient recruitment and retention in this eBook by providing practical tips, tools, and ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
Breaking Biology Technology: